‘Switchable’ CAR-T startup raises $112 million
AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies that can be turned “on” or “off” with a goal to more safely and effectively treat cancer patients.
22 Oct 13:34 · STAT